ML082950486
| ML082950486 | |
| Person / Time | |
|---|---|
| Site: | Harris, Brunswick, Crystal River, Robinson  |
| Issue date: | 10/13/2008 |
| From: | Mccabe B Progress Energy Carolinas |
| To: | Document Control Desk, Office of Nuclear Reactor Regulation |
| References | |
| PE&RAS-08-065 | |
| Download: ML082950486 (4) | |
Text
10 CFR 26, Appendix A, Subpart B, Section 2.8(e)(4)
PO Box 1551 41-1 Fayetteville Street Mall Raleigh NC 27602 Serial: PE&RAS-08-065 October 13, 2008 United States Nuclear Regulatory Commission ATTENTION: Document Control Desk Washington, DC 20555-0001 BRUNSWICK STEAM ELECTRIC PLANT, UNIT NOS. 1 AND 2 DOCKET NOS. 50-325 AND 50-324 / LICENSE NOS. DPR-71 AND DPR-62 SHEARON HARRIS NUCLEAR POWER PLANT, UNIT NO. 1 DOCKET NO. 50-400 / LICENSE NO. NPF-63 H. B. ROBINSON STEAM ELECTRIC PLANT, UNIT NO. 2 DOCKET NO. 50-261 / LICENSE NO. DPR-23 CRYSTAL RIVER UNIT 3 NUCLEAR GENERATING PLANT DOCKET NO. 50-302 / LICENSE NO. DPR-72 10 CFR 26 UNSATISFACTORY FITNESS-FOR-DUTY BLIND PERFORMANCE TESTING RESULT Ladies and Gentlemen:
Pursuant to 10 CFR 26, Appendix A, Subpart B, Section 2.8(e)(4), Carolina Power & Light Company, now doing business as Progress Energy Carolinas, Inc. (PEC), and Florida Power Corporation, now doing business as Progress Energy Florida, Inc. (PEF), are reporting an unsatisfactory blind performance testing result from Quest Diagnostics for the PEC and PEF Fitness-For-Duty Program.
On August 23, 2008, Quest Diagnostics reported a false positive blind test result to Progress Energy. This condition was entered into the Progress Energy Corrective Action Program and an investigation was initiated. The cause was an insufficient volume of wash solvent to adequately wash the injection syringe between all sample injections of the batch. The Quest Diagnostics report to Progress Energy is enclosed. Quest Diagnostics has taken corrective actions as discussed in the enclosure. Quest Diagnostics has also revised their standard operating procedure to address this issue.
This document contains no new regulatory commitments.
Please contact Bill Isom at (919) 546-2995 if you need additionalinformation.
Sincerely, Brian McCabe Manager - Nuclear Regulatory Affairs DBM
Enclosure:
Quest Diagnostics Letter Dated September 23, 2008
,XA
United States Nuclear Regulatory Commission PE&RAS-08-065 Page 2 c:
Luis Reyes, USNRC Regional Administrator - Region II F. Saba, NRR Project Manager - BSEP, Unit Nos. 1 and 2; CR3 M. Vaaler, NRR Project Manager - SHNPP, Unit No. 1; HBRSEP, Unit No. 2 USNRC Resident Inspector - BSEP, Unit Nos. 1 and 2 USNRC Resident Inspector - CR3 USNRC Resident Inspector - SHNPP, Unit No. 1 USNRC Resident Inspector - HBRSEP, Unit No. 2
Quest Diagnostics Incorporated 3175 Presidential Drive Atlanta, GA 30340 770.452.1590 www.questdiagnostics.com Quest Diagnostics September 23, 2008 Bill Isom PEB 5 -NS Progress Energy 410 S. Wilmington Street Raleigh, NC 27601 Re: Blind Control 4944168, LAN 684313E
Dear Mr. Isom:
This letter is in response to your request for Quest Diagnostics to investigate the results of specimen identification number 4944168, Laboratory Accession Number (LAN) 684313E.
Based on the information provided, the specimen was a blind negative quality control sample that was submitted as a Retest for Cocaine Metabolites. The specimen should have tested Negative for Cocaine Metabolites and reported as "Failed to Reconfirm", however, the specimen demonstrated the presence of Cocaine Metabolites and was reported as "Reconfirmed". The laboratory has conducted a full investigation into this issue and provides the following summary of our findings:
The specimen 684313E was analyzed by Gas Chromtography/Mass Spectrometry (GC/MS) on August 22, 2008 on Load TXNCOMS0822003. The laboratory identified the presence of Cocaine Metabolite in the specimen at a concentration of 85 ng/mL and reported the specimen as Reconfirmed on August 23, 2008. Following notification from Cindy Cunningham that an error in reporting had occurred, the laboratory re-analyzed the specimen on August 30, 2008 and obtained a Negative result for Cocaine Metabolites.
As part of the investigation, the laboratory re-analyzed all other specimens on the initial GC/MS confirmation load (TXNCOMS0822003) for Cocaine Metabolites. The results of the re-analysis were consistent with the results originally reported for each specimen and no correction to previously reported results was required.
Based on a telephone conversation with you and Cindy Cunningham on September 12, 2008, it was determined that the laboratory was required to repeat confirmation analysis on all NRC-Regulated specimens that were reported Positive for Cocaine Metabolites between July 1, 2008 through September 12, 2008. The laboratory identified twenty specimens that were reported Positive for Cocaine Metabolites during this period and repeated confirmation analysis on each specimen. The results of the re-analysis were
consistent with the results originally reported for each specimen and no correction to previously reported results was required.
The laboratory identified the cause of the blind negative control failure to be related to insufficient wash solvent volume for the number of sample injections performed on the GC/MS instrument. Wash solvent is utilized to rinse the sample syringe between sample injections to prevent cross-contamination. The laboratory isolated the issue to two GC/MS instruments where the number of wash solvent containers was limited by the configuration of the instrument. In order to address this issue, the laboratory issued a memorandum to employees revising the protocol for analysis on these instruments to include re-filling of the wash solvent containers following every twenty sample injections. This corrective action will ensure the presence of adequate wash solvent volume for proper rinsing of the sample syringe between each injection to prevent contamination to subsequent specimens.
The data associated with this investigation and documentation of corrective action will be maintained on file by the laboratory for review by the NRC audit team during their scheduled September 30h -October 3rd on-site inspection.
If you have any questions pertaining to the information provided above, please do not hesitate to contact me directly at 770-936-5009.
Respectfully, Brian A. Brunelli Laboratory Director